IS7444A - Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum - Google Patents

Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum

Info

Publication number
IS7444A
IS7444A IS7444A IS7444A IS7444A IS 7444 A IS7444 A IS 7444A IS 7444 A IS7444 A IS 7444A IS 7444 A IS7444 A IS 7444A IS 7444 A IS7444 A IS 7444A
Authority
IS
Iceland
Prior art keywords
morpholinyl
treatment
inflammatory diseases
urea derivatives
urea
Prior art date
Application number
IS7444A
Other languages
English (en)
Icelandic (is)
Inventor
Ancliff Rachael
Mary Cook Caroline
David Eldred Colin
Martin Gore Paul
Andrew Harrison Lee
Alistair Hayes Martin
Teanby Hodgson Simon
Bruce Judd Duncan
Elaine Keeling Suzanne
Qing Lewell Xiao
Mills Gail
Michael Robertson Graeme
Swanson Stephen
John Walker Andrew
Wilkinson Mark
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7444A publication Critical patent/IS7444A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS7444A 2002-03-28 2004-09-13 Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum IS7444A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds
PCT/EP2003/003335 WO2003082861A2 (en) 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
IS7444A true IS7444A (is) 2004-09-13

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7444A IS7444A (is) 2002-03-28 2004-09-13 Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum

Country Status (23)

Country Link
US (1) US7622464B2 (https=)
EP (1) EP1487828B1 (https=)
JP (1) JP4465195B2 (https=)
KR (1) KR20040093488A (https=)
CN (1) CN1656092A (https=)
AR (1) AR040403A1 (https=)
AT (1) ATE413399T1 (https=)
AU (1) AU2003226757A1 (https=)
BR (1) BR0308780A (https=)
CA (1) CA2480106A1 (https=)
CY (1) CY1108652T1 (https=)
DE (1) DE60324535D1 (https=)
DK (1) DK1487828T3 (https=)
ES (1) ES2315519T3 (https=)
IL (1) IL164047A0 (https=)
IS (1) IS7444A (https=)
MX (1) MXPA04009459A (https=)
NO (1) NO20044448L (https=)
PT (1) PT1487828E (https=)
RU (1) RU2004127928A (https=)
SI (1) SI1487828T1 (https=)
TW (1) TW200400035A (https=)
WO (1) WO2003082861A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
CA2579207C (en) 2004-09-08 2011-10-18 Mitsubishi Pharma Corporation Morpholine compound
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
WO2022023496A2 (en) * 2020-07-29 2022-02-03 Universidade De Santiago De Compostela Functionalized isonitriles and products, preparation and uses thereof
WO2022031735A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
WO1995032196A1 (en) 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
NZ290788A (en) 1994-07-20 1999-07-29 Byk Gulden Lomberg Chem Fab Piperazine thiopyridines; used for controlling helicobacter bacteria
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
AU1122399A (en) 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
ATE413399T1 (de) 2008-11-15
IL164047A0 (en) 2005-12-18
NO20044448L (no) 2004-10-26
AU2003226757A1 (en) 2003-10-13
ES2315519T3 (es) 2009-04-01
TW200400035A (en) 2004-01-01
US20060063765A1 (en) 2006-03-23
CY1108652T1 (el) 2014-08-13
SI1487828T1 (sl) 2009-04-30
CA2480106A1 (en) 2003-10-09
WO2003082861A3 (en) 2004-03-11
JP4465195B2 (ja) 2010-05-19
US7622464B2 (en) 2009-11-24
RU2004127928A (ru) 2005-06-27
EP1487828B1 (en) 2008-11-05
DK1487828T3 (da) 2009-02-02
PT1487828E (pt) 2009-01-06
DE60324535D1 (de) 2008-12-18
KR20040093488A (ko) 2004-11-05
EP1487828A2 (en) 2004-12-22
CN1656092A (zh) 2005-08-17
JP2005526815A (ja) 2005-09-08
WO2003082861A2 (en) 2003-10-09
MXPA04009459A (es) 2005-01-25
AR040403A1 (es) 2005-04-06
BR0308780A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
IS7648A (is) Dífenýlasetídínónafleiður til að meðhöndla fituefnaskiptasjúkdóma
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
NO20044054L (no) Administrering av midler for behandling av betennelse
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
IS7738A (is) Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
DK1342881T3 (da) Opskummet syrebehandlingsvæske
IS7710A (is) Heterósýklísk setin píperasín til notkunar við meðferð á geðklofa
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS8233A (is) Própíónsýruafleiður sem eru gagnlegar í meðhöndlun á fitusjúkdómum
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
DK1597171T3 (da) Terapeutisk mikroskum
EP1744740A4 (en) PHENOXYALKYCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
DK1553950T3 (da) Terapeutisk behandling
NO20050689L (no) Terapeutisk anvendelse
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
IS8390A (is) Notkun á gaboxadóli við meðhöndlun á svefnleysi
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
IS7537A (is) Notkun á nýjum etónógestrel esterum.